Search research articles
Contact Us
Filters
Showing results (151-160 of 184) with videos related to
Page
of 19
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 5, 2020
NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of <sup>177</sup>Lu-DOTATATE Peptide Receptor Radionuclide Therapy
Thomas A Hope, Lisa Bodei, Jennifer A Chan, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 26, 2021
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals
Teja Muralidhar Kalidindi, Sang-Gyu Lee, Katerina Jou, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 26, 2026
Delta-like Ligand 3-Directed <sup>225</sup>Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models
Tran T Hoang, David Bauer, Aidan Ingham, et al.
Neuroendocrinology
|
April 18, 2019
Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms
Somer Matar, Anna Malczewska, Kjell Oberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 1, 2023
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors
Thomas A Hope, Martin Allen-Auerbach, Lisa Bodei, et al.
Neuroendocrinology
|
May 24, 2022
Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE
Nitya Raj, Kelley Coffman, Tiffany Le, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 6, 2025
Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After Multimodality Brain Metastasis-Directed Treatment Including [<sup>177</sup>Lu]Lu-PSMA-617
Brandon S Imber, Kenny Kwok Hei Yu, Wassim Abida, et al.
Annals of Surgical Oncology
|
May 19, 2021
Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest)
Irvin M Modlin, Mark Kidd, Kjell Oberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 15, 2023
Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs
Lisa Bodei, R Michael Tuttle, Ravinder K Grewal, et al.
Neuroendocrinology
|
January 18, 2019
NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease
Anna Malczewska, Kjell Oberg, Lisa Bodei, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 184) with videos related to
Sort By:
Page
of 19
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 5, 2020
NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of <sup>177</sup>Lu-DOTATATE Peptide Receptor Radionuclide Therapy
Thomas A Hope, Lisa Bodei, Jennifer A Chan, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 26, 2021
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals
Teja Muralidhar Kalidindi, Sang-Gyu Lee, Katerina Jou, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 26, 2026
Delta-like Ligand 3-Directed <sup>225</sup>Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models
Tran T Hoang, David Bauer, Aidan Ingham, et al.
Neuroendocrinology
|
April 18, 2019
Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms
Somer Matar, Anna Malczewska, Kjell Oberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 1, 2023
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors
Thomas A Hope, Martin Allen-Auerbach, Lisa Bodei, et al.
Neuroendocrinology
|
May 24, 2022
Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE
Nitya Raj, Kelley Coffman, Tiffany Le, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 6, 2025
Symptomatic Prostate-Specific Membrane Antigen PET-Positive Radionecrosis After Multimodality Brain Metastasis-Directed Treatment Including [<sup>177</sup>Lu]Lu-PSMA-617
Brandon S Imber, Kenny Kwok Hei Yu, Wassim Abida, et al.
Annals of Surgical Oncology
|
May 19, 2021
Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest)
Irvin M Modlin, Mark Kidd, Kjell Oberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 15, 2023
Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs
Lisa Bodei, R Michael Tuttle, Ravinder K Grewal, et al.
Neuroendocrinology
|
January 18, 2019
NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease
Anna Malczewska, Kjell Oberg, Lisa Bodei, et al.
Page
of 19